. 2014 Jan-Feb;11(1-2):10–22.

TABLE 5.

Relapse rates by baseline severity

OPEN-LABEL BASELINE MADRS TOTAL SCORE	PLACEBO n^a (%)	LEVOMILNACIPRAN ER 40–120MG/DAY n^a (%)	HAZARD RATIO
OPEN-LABEL BASELINE MADRS TOTAL SCORE	PLACEBO n^a (%)	LEVOMILNACIPRAN ER 40–120MG/DAY n^a (%)	Estimate (95% CI)	P Value
≥26	16/82 (19.5)	25/170 (14.7)	0.724 (0.387, 1.357)	0.3137
≥28	14/70 (20.0)	19/132 (14.4)	0.672 (0.337, 1.340)	0.2588
≥30	13/53 (24.5)	16/95 (16.8)	0.627 (0.301, 1.303)	0.2108
≥32	10/39 (25.6)	11/73 (15.1)	0.496 (0.211, 1.170)	0.1093
≥34	6/25 (24.0)	5/44 (11.4)	0.392 (0.119, 1.286)	0.1223
≥36	5/13 (38.5)	3/25 (12.0)	0.216 (0.051, 0.910)	0.0368

n^a = number of patients who relapsed/number of patients with MADRS open-label baseline total score.

Hazard ratio, 95% CI, and P value are based on Cox proportional hazards model with treatment group as the explanatory variable.

MADRS: Montgomery-Åsberg Depression Rating Scale; ER: extended-release; CI; confidence Interval